OpenURL Connection Search

Select item for more details and to access through your institution.

Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Published in:
2015
By:
- Mesa, Ruben A;
- Verstovsek, Srdan;
- Gupta, Vikas;
- Mascarenhas, John O;
- Atallah, Ehab;
- Burn, Timothy;
- Sun, William;
- Sandor, Victor;
- Gotlib, Jason
Publication type:
journal article
Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)
Published in:
2013
By:
- Chen, Xuejun;
- Williams, William V.;
- Sandor, Victor;
- Yeleswaram, Swamy
Publication type:
Journal Article
Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF).
Published in:
Journal of Clinical Pharmacology, 2013, v. 53, n. 7, p. 721, doi. 10.1002/jcph.102
By:
- Chen, Xuejun;
- Williams, William V.;
- Sandor, Victor;
- Yeleswaram, Swamy
Publication type:
Article
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
Published in:
Journal of Hematology & Oncology, 2013, v. 6, n. 1, p. 3, doi. 10.1186/1756-8722-6-81
By:
- Talpaz, Moshe;
- Paquette, Ronald;
- Afrin, Lawrence;
- Hamburg, Solomon I.;
- Prchal, Josef T.;
- Jamieson, Katarzyna;
- Terebelo, Howard R.;
- Ortega, Gregory L.;
- Lyons, Roger M.;
- Tiu, Ramon V.;
- Winton, Elliott F.;
- Natrajan, Kavita;
- Odenike, Olatoyosi;
- Claxton, David;
- Peng, Wei;
- O'Neill, Peter;
- Erickson-Viitanen, Susan;
- Leopold, Lance;
- Sandor, Victor;
- Levy, Richard S.
Publication type:
Article
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Published in:
2014
By:
- Verstovsek, Srdan;
- Passamonti, Francesco;
- Rambaldi, Alessandro;
- Barosi, Giovanni;
- Rosen, Peter J;
- Rumi, Elisa;
- Gattoni, Elisabetta;
- Pieri, Lisa;
- Guglielmelli, Paola;
- Elena, Chiara;
- He, Shui;
- Contel, Nancy;
- Mookerjee, Bijoyesh;
- Sandor, Victor;
- Cazzola, Mario;
- Kantarjian, Hagop M;
- Barbui, Tiziano;
- Vannucchi, Alessandro M
Publication type:
journal article
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Published in:
Cancer (0008543X), 2014, v. 120, n. 4, p. 513, doi. 10.1002/cncr.28441
By:
- Verstovsek, Srdan;
- Passamonti, Francesco;
- Rambaldi, Alessandro;
- Barosi, Giovanni;
- Rosen, Peter J.;
- Rumi, Elisa;
- Gattoni, Elisabetta;
- Pieri, Lisa;
- Guglielmelli, Paola;
- Elena, Chiara;
- He, Shui;
- Contel, Nancy;
- Mookerjee, Bijoyesh;
- Sandor, Victor;
- Cazzola, Mario;
- Kantarjian, Hagop M.;
- Barbui, Tiziano;
- Vannucchi, Alessandro M.
Publication type:
Article

Found: 6

Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.

Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)

Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF).

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.